FOXM1 and prostate cancer: Thus, the knockout of ATG7, Beclin-1, or treatment with CQ restored the antitumor effect of docetaxel, demonstrating that either autophagy or FOXM1 may be potential targets for combined therapies with docetaxel to treat metastatic prostate cancer patients (81).